Clinical Trial Update: Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis [Phase 3]

View source ↗

Summary

Completed Phase 3 trial evaluating a live attenuated vaccine as an immune-based preventive against COVID-19-associated sepsis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Live attenuated vaccine (investigational)

Snippet

Sponsor: Louisiana State University Health Sciences Center in New Orleans | Conditions: Sepsis Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2024-11-26